29 August 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Share Awards to Executive Directors
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announce that on 28 August 2025, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan ("LTIP") over 374,318 ordinary shares in the Company (representing approximately 0.55 percent of the Company's issued share capital) to the Executive Directors listed below.
|
Name |
Position |
Number of Share Awards |
|
David Hallas |
Chief Executive Officer |
215,106 |
|
Chris Wilks |
Chief Financial Officer |
159,212 |
These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company's 2025 Annual Report which was published on 28 August 2025.
In addition, on 28 August 2025 nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 60,295 ordinary shares in the Company (representing approximately 0.09 percent of the Company's issued share capital) to the two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2025.
|
Name |
Position |
Number of Deferred Share Options |
|
David Hallas |
Chief Executive Officer |
35,472 |
|
Chris Wilks |
Chief Financial Officer |
24,823 |
As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years and are subject to malice and clawback provisions.
-Ends-
For further information please contact:
|
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher
|
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Lydia Zychowska
|
020 7597 5970
|
|
Equity Development Hannah Crowe Matt Evans
|
020 7065 2692 |
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700 ecoanimalhealth@icrhealthcare.com
|
|
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a. |
Name |
David Hallas
|
||||||||||||
|
2. |
Reason for the notification |
|||||||||||||
|
a. |
Position/status |
Chief Executive Officer
|
||||||||||||
|
b. |
Initial notification /Amendment
|
Initial notification |
||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
|
a. |
Name |
Eco Animal Health Group Plc |
||||||||||||
|
b. |
LEI |
2138009XN9DJ3YP70B55 |
||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
|
||||||||||||
|
b. |
Nature of the transaction |
1. Award of nominal cost conditional share awards under the Company's LTIP ("LTIP") 2. Nominal cost share awards under the Company's Deferred Bonus Plan ("DBS"). |
||||||||||||
|
c. |
Price(s) and volume(s) |
|
||||||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
|
||||||||||||
|
e. |
Date of the transaction |
28 August 2025 |
||||||||||||
|
f. |
Place of the transaction |
Off Market
|
||||||||||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a. |
Name |
Chris Wilks
|
||||||||||||
|
2. |
Reason for the notification |
|||||||||||||
|
a. |
Position/status |
Chief Financial Officer
|
||||||||||||
|
b. |
Initial notification /Amendment
|
Initial notification |
||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
|
a. |
Name |
Eco Animal Health Group Plc |
||||||||||||
|
b. |
LEI |
2138009XN9DJ3YP70B55 |
||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
|
||||||||||||
|
b. |
Nature of the transaction |
1. Award of nominal cost conditional share awards under the Company's LTIP ("LTIP") 2. Nominal cost share awards under the Company's Deferred Bonus Plan ("DBS"). |
||||||||||||
|
c. |
Price(s) and volume(s) |
|
||||||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
|
||||||||||||
|
e. |
Date of the transaction |
28 August 2025 |
||||||||||||
|
f. |
Place of the transaction |
Off Market
|
||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
